News about "Drug Development"

TCS Launches AgentHub to Scale Agentic AI Across Drug Development

TCS has launched ADD AgentHub, an enterprise-ready agentic AI platform designed to transform clinical development and pharmacovigilance while maintaining human oversight, regulatory compliance and auditability.

Drug Development | 18/08/2026 | By News Bureau |  117

Argo Biopharma Doses First Patient in Phase 1 siRNA Trial

Argo Biopharma has dosed the first participant in the phase I trial of BW-41012, its Factor XI-targeting siRNA therapy for preventing thromboembolic diseases.

Drug Development | 22/07/2026 | By News Bureau |  136

Bristol Myers Squibb Partners with NVIDIA to Build AI Factory

Bristol Myers Squibb and NVIDIA are building an Artificial Intelligence (AI) factory to accelerate drug discovery using advanced AI infrastructure and proprietary life sciences models.

Drug Development | 22/07/2026 | By News Bureau

Sino Biopharma and AstraZeneca Sign Licensing Deal for TQC3721

Sino Biopharmaceutical has signed an exclusive licensing agreement with AstraZeneca to develop, manufacture, and commercialise TQC3721, a novel PDE3/4 inhibitor for respiratory diseases.

Drug Development | 09/07/2026 | By News Bureau |  108

Ionis Completes Enrollment in Phase 3 REVEAL Study for Angelman Syndrome

Ionis has completed enrollment in the pivotal Phase 3 REVEAL study of obudanersen for Angelman syndrome, with topline clinical trial results expected in the second half of 2027.

Drug Development | 06/07/2026 | By Akanki |  244

Lupin Secures EMA Approval for Expanded NaMuscla Pediatric Use

Lupin has received EMA approval to expand the pediatric indication of NaMuscla, including two new capsule strengths of 62 mg and 83 mg.

Drug Development | 03/07/2026 | By News Bureau |  340

Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 3 ATLAS-UC Induction

Merck’s tulisokibart achieved both primary and key secondary endpoints in the phase 3 ATLAS-UC induction study, demonstrating significant efficacy in patients with moderately to severely active Ulcerative Colitis (UC).

Drug Development | 23/06/2026 | By News Bureau |  395

Bayer Completes Acquisition of Perfuse Therapeutics

Bayer has completed the acquisition of Perfuse Therapeutics, strengthening its ophthalmology pipeline and expanding its portfolio of innovative eye disease treatments.

Drug Development | 19/06/2026 | By News Bureau

Bayer to Acquire Perfuse Therapeutics to Boost Ophthalmology Pipeline

Bayer to acquire Perfuse Therapeutics, strengthening its ophthalmology pipeline with a potential disease-modifying therapy for glaucoma and diabetic retinopathy.

Drug Development | 07/05/2026 | By News Bureau |  104

Alloy Therapeutics and IPI Partners to Advance Next-Gen Antibody Discovery

Alloy Therapeutics and IPI collaborate to develop advanced VHH libraries for faster, more efficient next-generation antibody discovery.

Drug Development | 06/05/2026 | By News Bureau |  139